RxDoctor Payments Data

Syed Hassan, MD

Internal Medicine · Oviedo, FLNPI 1710935879

Payments from drug & device makers

$1,259in general payments, 2019–2025

Across 47 payments — averaging $26.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$425
  • AstraZeneca$133
  • Gilead$121
  • Celonova Biosciences, Inc.$112
  • GSK$88
  • Bayer$83
  • plus $298 from 11 others

What the payments were for

  • Food & beverage$1,24299%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,259 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$111,937
Medicare patients
129
Services billed
1,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate70$72,556
EliquisApixaban67$66,211
TrulicityDulaglutide43$63,063
MounjaroTirzepatide23$25,719
XareltoRivaroxaban15$23,477
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$21,996
OzempicSemaglutide22$20,657
FarxigaDapagliflozin Propanediol17$14,461
EntrestoSacubitril/Valsartan12$12,535
Repatha SureclickEvolocumab14$8,749
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$6,356
Venlafaxine Hcl ErVenlafaxine Hcl12$2,369
Albuterol Sulfate HfaAlbuterol Sulfate93$2,351
Gabapentin97$2,303
Rosuvastatin Calcium189$2,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$16$88,78266 claims
PfizerEliquis$17$66,21167 claims
Johnson & JohnsonXarelto$425$23,47715 claims
GSKTrelegy Ellipta$88$21,99626 claims
Novo NordiskOzempic$34$20,65722 claims
AstraZenecaFarxiga$133$14,46117 claims
AbbVieArmour Thyroid, Synthroid$16$2,11333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Oviedo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →